Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Majem · SciRah

Researcher profile · Semantic Scholar

M. Majem

Share profile

M. Majem — researcher profile on SciRah

h-index: 50
Works: 249
Citations: 20K

Most-cited papers

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer
H. Wakelee, M. Liberman, T. Kato, M. Tsuboi +15 more
2023New England Journal of Medicine871 citations Open access
Semantic Scholar
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
M. Tsuboi, R. Herbst, T. John, T. Kato +16 more
2023New England Journal of Medicine550 citations
Semantic Scholar
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Myung-Ju Ahn, B. Cho, E. Felip, I. Korantzis +26 more
2023New England Journal of Medicine458 citations Open access
Semantic Scholar
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Cai-Cun Zhou, Ke-Jing Tang, B. Cho, Bao-Gang Liu +24 more
2023New England Journal of Medicine329 citations
Semantic Scholar
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
R. Herbst, Yi-Long Wu, T. John, C. Grohé +21 more
2023Journal of Clinical Oncology324 citations Open access
Semantic Scholar
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
M. Provencio, R. Serna-Blasco, E. Nadal, A. Insa +25 more
2022Journal of Clinical Oncology272 citations Open access
Semantic Scholar
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
J. Chmielecki, J. Gray, Ying Cheng, Y. Ohe +11 more
2023Nature Communications271 citations Open access
Semantic Scholar
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
J. Spicer, M. Garassino, Heather A. Wakelee, M. Liberman +17 more
2024The Lancet259 citations Open access
Semantic Scholar
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
R. Herbst, M. Majem, F. Barlesi, E. Carcereny +12 more
2022Journal of Clinical Oncology250 citations Open access
Semantic Scholar
5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.
R. Herbst, E. Garon, Dong-Wan Kim, B. Cho +15 more
2021Journal of Thoracic Oncology240 citations Open access
Semantic Scholar
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Yi-Long Wu, T. John, C. Grohé, M. Majem +18 more
2021Journal of Thoracic Oncology146 citations Open access
Semantic Scholar
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
M. Provencio, E. Nadal, A. Insa, Rosario García Campelo +19 more
2024The Lancet Oncology89 citations Open access
Semantic Scholar
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
R. Soo, Jy Han, U. Dafni, B. Cho +25 more
2021Annals of Oncology86 citations Open access
Semantic Scholar
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
Roy S. Herbst, Thomas John, C. Grohe, J. Goldman +19 more
2025Nature Medicine85 citations Open access
Semantic Scholar
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
J. Remon, B. Besse, S. Aix, A. Callejo +18 more
2023Annals of Oncology70 citations Open access
Semantic Scholar
Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2.
Y. Tsutani, J. Goldman, S. Dacic, Y. Yatabe +5 more
2023Clinical Lung Cancer66 citations Open access
Semantic Scholar
Antibiotic-exposed patients with non-small cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
A. Cortellini, B. Ricciuti, F. Facchinetti, J. Alessi +22 more
2021Annals of Oncology66 citations Open access
Semantic Scholar
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
M. Casarrubios, M. Provencio, E. Nadal, A. Insa +21 more
2022Journal for ImmunoTherapy of Cancer63 citations Open access
Semantic Scholar
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
M. Casarrubios, A. Cruz-Bermúdez, E. Nadal, A. Insa +26 more
2021Clinical Cancer Research59 citations Open access
Semantic Scholar
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
J. Gray, M. Ahn, G. Oxnard, F. Shepherd +18 more
2023Clinical Cancer Research57 citations
Semantic Scholar
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
M. Riudavets, E. Auclin, M. Mosteiro, N. Dempsey +34 more
2022European Journal of Cancer55 citations Open access
Semantic Scholar
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer
R. Palmero, Á. Taus, S. Viteri, M. Majem +13 more
2021JCO Precision Oncology51 citations
Semantic Scholar
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Laura Q. M. Chow, F. Barlesi, E. Bertino, M. J. van den Bent +15 more
2022Clinical Cancer Research34 citations Open access
Semantic Scholar
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
A. Cortellini, L. Brunetti, G. Di Fazio, E. Garbo +103 more
2025Journal for ImmunoTherapy of Cancer32 citations Open access
Semantic Scholar
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
A. Cortellini, B. Ricciuti, V. Vaz, D. Soldato +31 more
2022Journal for ImmunoTherapy of Cancer32 citations Open access
Semantic Scholar
Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.
J. Gray, A. Markovets, T. Reungwetwattana, M. Majem +15 more
2024Journal of Thoracic Oncology28 citations Open access
Semantic Scholar
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
R. Herbst, M. Tsuboi, T. John, T. Kato +16 more
2023Journal of Clinical Oncology28 citations
Semantic Scholar
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
J. Remon, B. Besse, S. Aix, Ana Callejo +18 more
2024Journal of Clinical Oncology27 citations Open access
Semantic Scholar
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
M. Majem, J. Goldman, T. John, C. Grohé +20 more
2022Clinical Cancer Research23 citations Open access
Semantic Scholar
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
V. Gregorc, M. González-Cao, S. Salvagni, A. Koumarianou +11 more
2024Journal of Clinical Oncology22 citations Open access
Semantic Scholar
Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review.
C. Blakely, W. Weder, L. Bubendorf, Jianxing He +3 more
2023Lung Cancer22 citations Open access
Semantic Scholar
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial.
T. John, C. Grohé, J. Goldman, F. Shepherd +16 more
2023Journal of Thoracic Oncology22 citations Open access
Semantic Scholar
Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors
L. Alserawan, M. Mulet, G. Anguera, M. Riudavets +7 more
2024Cancers21 citations Open access
Semantic Scholar
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
Tom John, C. Grohe, J. Goldman, T. Kato +16 more
2024Journal of Clinical Oncology21 citations
Semantic Scholar
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021)
M. Majem, R. de las Peñas, J. Virizuela, L. Cabezón-Gutiérrez +6 more
2022Clinical and Translational Oncology21 citations Open access
Semantic Scholar
A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
E. Felip, M. Majem, B. Doger, T. Clay +12 more
2022Journal of Clinical Oncology21 citations
Semantic Scholar
OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy
A. Romero, E. Nadal, R. Serna, A. Insa +23 more
2021Journal of Thoracic Oncology21 citations Open access
Semantic Scholar
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
D. Waterhouse, Sacha I. Rothschild, C. Dooms, B. Mennecier +17 more
2024Lung Cancer20 citations Open access
Semantic Scholar
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
Carlos Zamora Atenza, G. Anguera, Mariona Riudavets Melià, Letícia Alserawan De Lamo +7 more
2022Cancer Immunology and Immunotherapy20 citations
Semantic Scholar
Sex-related differences in the efficacy and toxicity of cancer treatments
Ana Santaballa Bertrán, José Antonio Marcos Rodríguez, A. Cardeña-Gutiérrez, Virginia Martinez-Callejo +4 more
2025Clinical and Translational Oncology17 citations Open access
Semantic Scholar
Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents
C. Zamora, M. Riudavets, G. Anguera, L. Alserawan +10 more
2021Cancer Immunology and Immunotherapy17 citations
Semantic Scholar
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
H. Wakelee, M. Liberman, T. Kato, M. Tsuboi +16 more
2023Journal of Clinical Oncology16 citations Open access
Semantic Scholar
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
Melina Peressini, R. García-Campelo, Bartomeu Massutí, C. Martí +39 more
2024Clinical Cancer Research15 citations
Semantic Scholar
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
M. Krebs, Martin Forster, M. Majem, J. Peguero +9 more
2024JTO Clinical and Research Reports14 citations Open access
Semantic Scholar
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
Bernard Gaston Doger de Spéville, E. Felip, M. Forster, M. Majem +7 more
2023Journal of Clinical Oncology13 citations Open access
Semantic Scholar
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)
A. D. Di Giacomo, M. Schenker, J. Medioni, S. Mandziuk +6 more
2024ESMO Open11 citations Open access
Semantic Scholar
Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).
Charu Aggarwal, A. Martínez-Martí, M. Majem, F. Barlesi +12 more
2024Journal of Clinical Oncology11 citations
Semantic Scholar
RET Fusion Testing in Patients With NSCLC: The RETING Study
Esther Conde, S. Hernandez, J. L. Rodríguez Carrillo, R. Martínez +36 more
2024JTO Clinical and Research Reports11 citations Open access
Semantic Scholar
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
D. Isla, A. Sánchez, J. Casal, M. Cobo +4 more
2023Journal of Clinical Medicine11 citations Open access
Semantic Scholar
PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
A. Eggermont, P. Ascierto, N. Khushalani, D. Schadendorf +14 more
2022Future Oncology11 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Dómine×12
Invite
M. Dómine — researcher profile on SciRah
T. Kato×8
Invite
T. Kato — researcher profile on SciRah
M. Tsuboi×8
Invite
M. Tsuboi — researcher profile on SciRah
R. Herbst×8
Invite
R. Herbst — researcher profile on SciRah

D. Rodríguez-Abreu

×7

Invite

D. Rodríguez-Abreu — researcher profile on SciRah

Invite

J. Goldman — researcher profile on SciRah

Invite

F. Shepherd — researcher profile on SciRah

Invite

Yi-Long Wu — researcher profile on SciRah

Invite

E. Nadal — researcher profile on SciRah

A. Martínez-Martí×7

Invite

A. Martínez-Martí — researcher profile on SciRah

E. Carcereny×7

Invite

E. Carcereny — researcher profile on SciRah

F. de Marinis×6

Invite

F. de Marinis — researcher profile on SciRah